LUNAC Therapeutics Secures Over €3M to Develop Novel Anticoagulants
LUNAC Therapeutics has spun out of the University of Leeds with €3.09M of funding from the university and the VC firm Epidarex Capital for the development of anticoagulants with a lower risk for bleeding than those currently available. The new anticoagulants